Please wait while the formulary information is being retrieved.
AMVUTTRA (vutrisiran sodium)
- transthyretin familial amyloid polyneuropathy
25 mg/0.5 mL subcutaneous syringe
- Inject 0.5 milliliter (25 mg) by subcutaneous route every 3 months
Default screening record
- Inject 0.5 milliliter (25 mg) by subcutaneous route every 3 months
- None
Contraindicated
- None
Severe
Moderate
- None
- None
Contraindicated
- Night blindness
- Vitamin A deficiency
Severe
Moderate
- None
AMVUTTRA (vutrisiran sodium)
- transthyretin familial amyloid polyneuropathy
- None
- Arthralgia
- Dyspnea
- Vitamin A deficiency
More Frequent
Severe
Less Severe
- Heart block
- Injection site erythema
- Injection site pain
- Injection site sequelae
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- None
Less Severe
- None
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Vutrisiran
Safety and effectiveness not established in pediatric patients.
- 1 Day – 18 Years
- Safety and effectiveness not established in pediatric patients.
Vutrisiran
- Severity Level:
2
- Additional Notes: Insuff human data; supplement with rda of vitamin a
Contraindicated
None
General | Excretion Potential | Effect on Infant | Notes |
None |
Precaution Exists
Vutrisiran
Insufficient human data
General | Excretion Potential | Effect on Infant | Notes |
Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient human data |
No Known Risk
None
General | Excretion Potential | Effect on Infant | Notes |
None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
Transthyretin familial amyloid polyneuropathy | |
E85.1 | Neuropathic heredofamilial amyloidosis |
E85.82 | Wild-type transthyretin-related (ATTr) amyloidosis |
G63 | Polyneuropathy in diseases classified elsewhere |
0-9 | A-Z |
---|---|
E85.1 | Neuropathic heredofamilial amyloidosis |
E85.82 | Wild-type transthyretin-related (ATTr) amyloidosis |
G63 | Polyneuropathy in diseases classified elsewhere |
Formulary Reference Tool